Long-term survival in a patient with advanced non-smoking lung adenocarcinoma and no EGFR mutation after comprehensive therapy with EGFR-TKI-based therapy-Reference-Cited by-同舟云学术

Long-term survival in a patient with advanced non-smoking lung adenocarcinoma and no EGFR mutation after comprehensive therapy with EGFR-TKI-based therapy

Published:2022-01-14 Issue:2 Volume:101 Page:e28583
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Zhang Qianyu,Liu Meiling,Zhong Yunchao,Zhang Kang

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference7 articles.

1. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer;Cochrane Database Syst Rev,2010

2. The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer;Zhao;Sci Rep,2017

3. Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer;Wang;Zhonghua Zhong Liu Za Zhi,2008

4. How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care;Kris;Oncologist,2005

5. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis;Liao;J Thorac Oncol,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol;2024-04-16

2. PATIENTS WITH EGFR-MUTATED LUNG ADENOCARCINOMA AFTER PROGRESSION;ACTA MEDICA MEDITERR;2023

3. The 1q21.3 region driver gene EFNA3 promotes disease progression via inhibition of lung adenocarcinoma cell apoptosis;Translational Cancer Research;2022-05

4. Osimertinib;Reactions Weekly;2022-04